NASDAQ:PALI Palisade Bio (PALI) Stock Forecast, Price & News $1.49 +0.07 (+4.93%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$1.40▼$1.5350-Day Range$1.32▼$3.5252-Week Range$1.27▼$30.60Volume239,704 shsAverage Volume1.37 million shsMarket Capitalization$9.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Palisade Bio MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Palisade Bio. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.75% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 64.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PALI. Previous Next 2.0 News and Social Media Coverage News SentimentPalisade Bio has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Palisade Bio this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.25% of the stock of Palisade Bio is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($1.57) to ($0.90) per share.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Palisade Bio (NASDAQ:PALI) StockPalisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.Read More Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PALI Stock News HeadlinesJune 1, 2023 | finanznachrichten.dePalisade Bio, Inc.: Palisade Bio Promotes J.D. Finley to Chief Executive OfficerJune 1, 2023 | msn.comPalisade Bio appoints J.D. Finley as permanent CEOJune 6, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 1, 2023 | finance.yahoo.comPalisade Bio Promotes J.D. Finley to Chief Executive OfficerMay 28, 2023 | americanbankingnews.comAnalyzing Genocea Biosciences (NASDAQ:GNCAQ) & Palisade Bio (NASDAQ:PALI)May 24, 2023 | finance.yahoo.comPalisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data ReadoutsMay 23, 2023 | msn.comPalisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMay 19, 2023 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Price Target Lowered to $16.00 at LADENBURG THALM/SH SHJune 6, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 18, 2023 | benzinga.comLadenburg Thalmann Maintains Buy on Palisade Bio, Lowers Price Target to $16May 17, 2023 | finance.yahoo.comPALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WESTMay 17, 2023 | msn.comLadenburg Thalmann Maintains Palisade Bio (PALI) Buy RecommendationMay 13, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Palisade Bio (PALI)May 12, 2023 | finanznachrichten.dePalisade Bio, Inc.: Palisade Bio Reports First Quarter 2023 Financial ResultsMay 12, 2023 | finance.yahoo.comPalisade Bio Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comPalisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization StudyMay 10, 2023 | americanbankingnews.comPalisade Bio (PALI) to Release Earnings on ThursdayApril 22, 2023 | marketwatch.comS-1: PALISADE BIO, INC.April 17, 2023 | finance.yahoo.comPalisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?April 12, 2023 | benzinga.comPremarket Mover: Palisade Bio Inc (PALI) Up 0.96%April 6, 2023 | msn.comPalisade (PALI) Enrolls First Patient in LB1148 Study in ChinaApril 6, 2023 | finance.yahoo.comPalisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148April 5, 2023 | marketwatch.comPalisade Bio Shares Rise After First Patient Dosed With Gastrointestinal DrugApril 5, 2023 | finanznachrichten.dePalisade Bio, Inc.: Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148April 5, 2023 | seekingalpha.comPalisade Bio shares plummet following a $6M registered direct offeringApril 5, 2023 | finance.yahoo.comPalisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148April 4, 2023 | marketwatch.comPalisade Bio Shares Down for a Second Day, Declining 10%See More Headlines PALI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PALI Company Calendar Last Earnings11/15/2021Today6/06/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,260,000.00 Net MarginsN/A Pretax Margin-4,958.00% Return on Equity-115.68% Return on Assets-89.99% Debt Debt-to-Equity RatioN/A Current Ratio10.88 Quick Ratio10.88 Sales & Book Value Annual Sales$10,000.00 Price / Sales991.67 Cash FlowN/A Price / Cash FlowN/A Book Value$4.24 per share Price / Book0.35Miscellaneous Outstanding Shares6,700,000Free Float6,613,000Market Cap$9.92 million OptionableNot Optionable Beta1.54 Key ExecutivesJ. D. FinleyDirector, Chief Executive & Financial OfficerRobert McRaeChief Operating OfficerRyker WillieVice President-Finance & ControllerJohn RodenrysChief Technology Officer & Executive VPHerbert B. SladeChief Medical OfficerKey CompetitorsFreeline TherapeuticsNASDAQ:FRLNTitan PharmaceuticalsNASDAQ:TTNPWindtree TherapeuticsNASDAQ:WINTIgnyte AcquisitionNASDAQ:IGNYAceragenNASDAQ:ACGNView All CompetitorsInsidersJohn David FinleyBought 7,350 shares on 8/23/2022Total: $1,176.00 ($0.16/share)John David FinleyBought 100,000 shares on 8/16/2022Total: $25,000.00 ($0.25/share)Thomas HallamBought 40,000 shares on 8/16/2022Total: $10,000.00 ($0.25/share)View All Insider Transactions PALI Stock - Frequently Asked Questions Should I buy or sell Palisade Bio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PALI shares. View PALI analyst ratings or view top-rated stocks. How have PALI shares performed in 2023? Palisade Bio's stock was trading at $5.20 at the start of the year. Since then, PALI stock has decreased by 71.5% and is now trading at $1.4801. View the best growth stocks for 2023 here. Are investors shorting Palisade Bio? Palisade Bio saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 114,600 shares, a decline of 65.0% from the April 30th total of 327,300 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.8% of the company's shares are sold short. View Palisade Bio's Short Interest. When is Palisade Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our PALI earnings forecast. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) issued its quarterly earnings data on Monday, November, 15th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.78. What is Palisade Bio's stock symbol? Palisade Bio trades on the NASDAQ under the ticker symbol "PALI." How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Palisade Bio's stock price today? One share of PALI stock can currently be purchased for approximately $1.48. How much money does Palisade Bio make? Palisade Bio (NASDAQ:PALI) has a market capitalization of $9.92 million and generates $10,000.00 in revenue each year. How can I contact Palisade Bio? Palisade Bio's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for the company is www.palisadebio.com. The company can be reached via phone at (858) 704-4900 or via email at investor@senecabio.com. This page (NASDAQ:PALI) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.